
Browsing restrictions can be lifted for a fee.
-4.66%
Bioatla, inc.
-1.10%
Avg of Sector
-0.49%
S&P500
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Bioatla, inc. (BCAB) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BCAB's short-term business performance and financial health. For the latest updates on BCAB's earnings releases, visit this page regularly.
According to the latest financial report, Bioatla, inc. (BCAB) reported an Operating Profit of -9.26M with an Operating Margin of -462.75% this period, representing a growth of 43.03% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Bioatla, inc. (BCAB) announced revenue of 2M, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Bioatla, inc. (BCAB) had total debt of 6.2M, with a debt ratio of 0.45. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Bioatla, inc. (BCAB) held Total Cash and Cash Equivalents of 7.12M, accounting for 0.51 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Bioatla, inc. (BCAB) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -462.75%%, and net margin of -489.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BCAB's profit trajectory and future growth potential.
According to the past four quarterly reports, Bioatla, inc. (BCAB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -7.5. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Bioatla, inc. (BCAB)'s Free Cash Flow (FCF) for the period is -7.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 52.84% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Bioatla, inc. (BCAB) has a Price-To-Earnings (PE) ratio of -0.22 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.